249 related articles for article (PubMed ID: 30171029)
1. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
2. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
3. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
[TBL] [Abstract][Full Text] [Related]
4. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
5. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
6. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
7. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Vatapalli R; Sagar V; Rodriguez Y; Zhao JC; Unno K; Pamarthy S; Lysy B; Anker J; Han H; Yoo YA; Truica M; Chalmers ZR; Giles F; Yu J; Chakravarti D; Carneiro B; Abdulkadir SA
Nat Commun; 2020 Aug; 11(1):4153. PubMed ID: 32814769
[TBL] [Abstract][Full Text] [Related]
8. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
9. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
10. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
11. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
12. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract][Full Text] [Related]
13. DISORDERED HISTONE METHYLATION IN HEMATOLOGICAL MALIGNANCIES THE CASE OF UTX/KDM6A.
Licht JD
Trans Am Clin Climatol Assoc; 2018; 129():24-36. PubMed ID: 30166694
[TBL] [Abstract][Full Text] [Related]
14. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
[TBL] [Abstract][Full Text] [Related]
15. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T; Dupéré-Richer D; Will CM; Small EC; Varghese N; Patel T; Nabet B; Popovic R; Oyer J; Bulic M; Zheng Y; Huang X; Shah MY; Maji S; Riva A; Occhionorelli M; Tonon G; Kelleher N; Keats J; Licht JD
Cell Rep; 2017 Oct; 21(3):628-640. PubMed ID: 29045832
[TBL] [Abstract][Full Text] [Related]
16. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
17. The role of DOT1L in the proliferation and prognosis of gastric cancer.
Song Z; Wei Z; Wang Q; Zhang X; Tao X; Wu N; Liu X; Qian J
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31939604
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.
Ju Han H; Sub Byun W; Ho Lee G; Kyung Kim W; Jang K; Yang S; Yang J; Woo Ha M; Hong S; Lee J; Shin J; Bong Oh K; Kook Lee S; Park HG
Bioorg Med Chem; 2021 Apr; 35():116072. PubMed ID: 33636429
[TBL] [Abstract][Full Text] [Related]
19. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Nassa G; Salvati A; Tarallo R; Gigantino V; Alexandrova E; Memoli D; Sellitto A; Rizzo F; Malanga D; Mirante T; Morelli E; Nees M; Åkerfelt M; Kangaspeska S; Nyman TA; Milanesi L; Giurato G; Weisz A
Sci Adv; 2019 Feb; 5(2):eaav5590. PubMed ID: 30775443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]